GARBUJO STEFANIA
Pubblicazioni
Barbieri, L., Salvioni, L., Banfi, A., Garbujo, S., Fiandra, L., Baioni, C., et al. (2025). Dual-Targeting Strategy to Repurpose Cetuximab with HFn Nanoconjugates for Immunotherapy of Triple-Negative Breast Cancer. ACS APPLIED MATERIALS & INTERFACES [10.1021/acsami.5c06626]. Dettaglio
Giustra, M., Arrigoni, F., Novati, B., Garbujo, S., Salvioni, L., Colombo, A., et al. (2024). Multidentate surfactants for improving stability and biological properties. Intervento presentato a: NANOMIB Conference. Recent Advances in Nanomedicine: Opportunities and Challenges, Milano. Dettaglio
di Miceli, N., Baioni, C., Barbieri, L., Danielli, D., Sala, E., Salvioni, L., et al. (2024). TGF-β Signaling Loop in Pancreatic Ductal Adenocarcinoma Activates Fibroblasts and Increases Tumor Cell Aggressiveness. CANCERS, 16(21) [10.3390/cancers16213705]. Dettaglio
Morelli, L., Ochoa, E., Salvioni, L., Davide Giustra, M., De Santes, B., Spena, F., et al. (2024). Microfluidic nanoparticle synthesis for oral solid dosage forms: A step toward clinical transition processes. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 652(5 March 2024) [10.1016/j.ijpharm.2024.123850]. Dettaglio
Ochoa, E., Morelli, L., Salvioni, L., Giustra, M., De Santes, B., Spena, F., et al. (2024). Co-processed materials testing as excipients to produce Orally Disintegrating Tablets (ODT) using binder jet 3D-printing technology. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 194(January 2024), 85-94 [10.1016/j.ejpb.2023.11.023]. Dettaglio